Breast cancer patients’ most important quality of life themes for a radiotherapy decision aid
Cheryl Roumen,
Hajar Hasannejadasl,
Rachelle Swart,
Daniela Raphael,
Leonard Wee,
Matthijs Sloep,
Desiree H.J.G. van den Bongard,
Helena Verkooijen,
Salina Thijssen,
Mirjam Velting,
Maaike Schuurman,
Nicola S. Russell,
Rianne Fijten,
Liesbeth J. Boersma
Affiliations
Cheryl Roumen
Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, Dr. Tanslaan 12, 6229 ET, Maastricht, the Netherlands; Corresponding author.
Hajar Hasannejadasl
Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, Dr. Tanslaan 12, 6229 ET, Maastricht, the Netherlands
Rachelle Swart
Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, Dr. Tanslaan 12, 6229 ET, Maastricht, the Netherlands
Daniela Raphael
Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, Dr. Tanslaan 12, 6229 ET, Maastricht, the Netherlands
Leonard Wee
Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, Dr. Tanslaan 12, 6229 ET, Maastricht, the Netherlands
Matthijs Sloep
Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, Dr. Tanslaan 12, 6229 ET, Maastricht, the Netherlands
Desiree H.J.G. van den Bongard
Department of Radiation Oncology, Amsterdam University Medical Centers, De Boelelaan 1117 and 1118, 1081 HV, Amsterdam, Amsterdam, the Netherlands
Helena Verkooijen
Division of Imaging and Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands
Salina Thijssen
Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, Dr. Tanslaan 12, 6229 ET, Maastricht, the Netherlands
Mirjam Velting
Dutch Breast Cancer Association, the Netherlands
Maaike Schuurman
Dutch Breast Cancer Association, the Netherlands
Nicola S. Russell
Department of Radiotherapy, The Netherlands Cancer Institute- Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands
Rianne Fijten
Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, Dr. Tanslaan 12, 6229 ET, Maastricht, the Netherlands
Liesbeth J. Boersma
Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, Dr. Tanslaan 12, 6229 ET, Maastricht, the Netherlands
Background and aim: The BRASA patient decision aid (BRASA-PtDA) facilitates shared decision making for breast cancer patients (BCPs) facing a radiotherapy treatment decision. During evaluations, patients indicated the wish for quantitative information on side effects. Therefore, this study assessed BCPs opinion on which and how information on side effects should be incorporated in the BRASA-PtDA. Methods: A workshop was organized with BCPs (n = 9), researchers (n = 5) and clinicians (n = 3). Subsequently, a survey was sent to BCPs (n = 744) investigating the generalisability of the workshop findings, and posing additional questions. The survey entailed multiple choice questions on quality of life themes, the use of a decision aid and risk communication. Results: The workshop revealed BCPs wish for a layered, all encompassing information system. Information on the impact of side effects on daily life was preferred above the risk of these side effects. The survey revealed that important quality of life (QoL) themes were having energy (81%; n = 605), arm function (61%; n = 452), pain (55%; n = 410). Despite the focus on qualitative effects in the workshop, 89% of the survey respondents also wanted to be informed on individualized risks of side effects. 54% Of the survey respondents had never heard of a PtDA. Conclusions: BCPs preferred information on the impact of side effects, but also their individualized risks on side effects. Most important QoL themes were having enough energy, arm function and pain. Consequently, the BRASA-PtDA should be reshaped, starting with quality of life themes, rather than side effects.